Observations placeholder
Gleevec
Identifier
019090
Type of Spiritual Experience
Number of hallucinations: 39
Background
A description of the experience
Imatinib (INN), marketed by Novartis as Gleevec (Canada, South Africa and the USA) or Glivec (Australia, Europe and Latin America), and sometimes referred to by its investigational name STI-571, is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML)
On Dec, 12, 2015: 20,269 people reported to have side effects when taking Gleevec. Among them, 39 people (0.19%) have Hallucination.
On Nov, 25, 2015: 20,267 people reported to have side effects when taking Gleevec. Among them, 3,515 people (17.34%) have Death.